Use somatic mutations to choose a personalized cancer vac...

Recent research indicates that a combination of a personalized vaccine and drug successfully reduces melanoma recurrence by 49%, showcasing significant advances in cancer treatment.

Tune in to Bloomberg TV this Saturday as Anixa Biosciences' Dr. Amit Kumar discusses groundbreaking cancer treatments and promising trial results.

Northwest Biotherapeutics has appointed Dr. Annalisa Jenkins as a strategic adviser to advance their innovative dendritic cell cancer vaccine platform, DCVax.

Anixa Biosciences, a biotech firm focused on cancer treatment, will present at the Water Tower Research Insights Conference on April 14, 2026.

Infinitopes has successfully raised a total of $35.1 million in seed funding, aimed at advancing its promising cancer vaccine ITOP1 towards clinical trials, targeting oesophageal cancer.

NEUVOGEN presented groundbreaking findings on its new cancer vaccine NGEN-143 at the AACR Annual Meeting, showcasing its potential against non-small cell lung cancer.

NEUVOGEN Inc. has announced the addition of Nobel laureate Dr. James P. Allison and Dr. Padmanee Sharma to its Scientific Advisory Board, enhancing its cancer vaccine expertise.

Anixa Biosciences, Inc. has received a Notice of Allowance for its ovarian cancer vaccine patent, marking a critical step in cancer prevention and treatment.

Esphera SynBio has raised $2 million in seed funding aiming to advance its nanomedicine vaccine platform for cancer and infectious diseases.

BioVaxys Technology Corp. presented promising new data regarding its DPX immune educating platform, highlighting its effectiveness in cancer vaccines.